Expression of Cyclooxygenase-1 and Cyclooxygenase-2 in normal and pathological human oral mucosa

Folia Histochemica et Cytobiologica

Volumn 48, Issue 4, 2010, Pages 555-563

  Mauro, Annamaria ^a   Lipari, Luana ^a   Leone, Angelo ^a   Tortorici, Silvia ^a   Burruano, Francesco ^a   Provenzano, Salvatore ^a   Gerbino, Aldo ^a   Buscemi, Maria ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Carcinoma; Cyclooxigenases; Dysplasia; Human oral mucosa; Hyperplasia

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MESSENGER RNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME LOCALIZATION; HUMAN; HUMAN TISSUE; MOUTH CARCINOMA; MOUTH DISEASE; MOUTH DYSPLASIA; MOUTH HYPERPLASIA; MOUTH MUCOSA; PROTEIN EXPRESSION;

EID: 79958044103     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.2478/v10042-010-0066-3     Document Type: Article

References (46)

1. Feng L, Sun W, Xia Y, et al. Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys. 1993;307(2):361-8.
2. Hla T and Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A. 1992;89(16):7384-8.
3. Kujubu DA, Reddy ST, Fletcher BS and Herschman HR. Expression of the protein product of the prostaglandin synthase- 2/ gene in mitogen-stimulated Swiss 3T3 cells. J Biol Chem. 1993;268:5425-30.
4. Shamma A, Yamamoto H, Doki Y et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res. 2000;6(4):1229-38.
5. Banerjee AG, Gopalakrishnan VK, Bhattacharya I and Vishwanatha JK. Deregulated cyclooxygenase-2 expression in oral premalignant tissues. Mol Cancer Ther. 2002;1(14): 1265-71.
6. Shibata M, Kodani I, Osaki M et al. Cyclo-oxigenase-1 and- 2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Oral Oncology. 2005;41:304-312.
7. Pannone G, Sanguedolce F, De Maria S, Farina E, Lo Muzio L, Serpico R, et al. Cyclooxygenase isozymes in oral squamous cell carcinoma:a real-time RT-PCR study with clinic pathological correlations. Int J Immunopathol Pharmacol. 2007;20(2):317-24.
8. Zhang S, Du Y, Tao J, Wu Y, Chen N. Expression of cytosolic phospholipase A2 and cyclooxygenase 2 and their significance in human oral mucosae, dysplasias and squamous cell carcinomas. ORL J Otorhinolaryngol Relat Spec. 2008;70(4): 242-8.
9. Sappayatosok K, Maneerat Y, Swasdison S, Viriyavejakul P, Dhanuthai K, Zwang J, et al. Expression of pro-inflammatory protein, iNOS, VEGF and COX-2 in oral squamous cell carcinoma (OSCC), relationship with angiogenesis and their clinico-pathological correlation. Med Oral Patol Oral Cir Bucal. 2009;14(7):E319-24.
10. McCormick DL, Phillips JM, Horn TL, Johnson WD, Steele VE, Lubet RA. Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors. Cancer Prev Res (Phila Pa). 2010;3(1):73-81.
11. Dempke W, Rie C, Grothey A and Schmoll HJ. Cyclooxygenase- 2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 2001;127(7):411-7.
12. Harris RE. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem. 2007;42:93-126.
13. Ghosh N, Chaki R, Mandal V, Mandal SC. COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 2010;62(2):233-44.
14. Mizuno K, Yamamoto S and Lands WE. Effects of nonsteroidal anti-inflammatory drugs on fatty acid cyclooxygenase and prostaglandin hydroperoxidase activities. Prostaglandins. 1982;23:743-57.
15. Terakado N, Shintani S, Yano J et al. Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncology. 2004;40:383-389.
16. Mizuno S, Kato K, Hashimoto A et al. Expression of cyclooxygenase- 2 in Gastrointestinal Carcinoid Tumors. J Gastroenterol Hepatol. 2006;21(8):1313-1319.
17. Klein T, Shephard P, Kleinert H and Kömhoff M. Regulation of cyclooxygenase-2 expression by cyclic AMP. Biochimica et Biophysica Acta. 2007;1773:1605-1618.
18. Tortorici S, Mauro A, Burruano F et al. Matrix metalloproteinase- 2 matrix metalloproteinase-9 and inducible nitric oxide synthase in oral leukoplakia: immunohistochemistry and RT-PCR analysis. J Biol Regul Homeost Agents. 2008; 22(2):125-30.
19. Lipari L, Mauro A, Tortorici S et al. Immunohistochemical and transcriptional expression of the matrix metalloproteinases MMP-2 and MMP-9 in normal and pathological human oral mucosa. J Biol Regul Homeostat Agents. 2009;23(4): 259-67.
20. Choi EM, Heo JI, Oh JY et al. COX-2 regulates p53 activity and inhibits DNA damage-induced apoptosis. Biochem Biophys Res Commun. 2005;328(4):1107-12.
21. Wang D and DuBois RN. Prostaglandins and cancer. Gut. 2006;55:115-122.
22. De Souza Pereira R. Selective cyclooxygenase-2 (COX-2) inhibitors used for preventing or regressing cancer. Recent Pat Anticancer Drug Discov. 2009;4(2):157-63.
23. Katoh H, Hosono K, Ito Y, Suzuki T, Ogawa Y, Kubo H, et al. COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems. Am J Pathol. 2010; 176(3):1469-83.
24. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB and De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 2004;215(1):1-20.
25. Goulart Filho JA, Nonaka CF, da Costa Miguel MC, de Almeida Freitas R and Galvao HC. Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma. Am J Otolaryngol. 2009;30(2):89-94.
26. Singh P, Mittal A. Current status of COX-2 inhibitors. Mini Rev Med Chem. 2008;8(1):73-90.
27. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Cyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers. J Gastrointest Cancer. 2007;38(2-4):78-82.
28. Breinig M, Schirmacher P, Kern MA. Cyclooxygenase-2 (COX-2)--a therapeutic target in liver cancer? Curr Pharm Des. 2007;13(32):3305-15.
29. Shinohara N, Kumagai A, Kanagawa K, Maruyama S, Abe T, Sazawa A, et al. Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon- alpha for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2009;39(11):720-6.
30. Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci USA. 2009;106(9):3372-7.
31. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology. 2009;17(2):55-67.
32. Ohtsu N, Takaoka K, Segawa E, Hashitani S, Noguchi K, Kishimoto H, et al. Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2. Oncol Rep. 2010;24(1):31-6.
33. Kwak YE, Jeon NK, Kim J, Lee EJ. The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma. Ann N Y Acad Sci. 2007;1095:99-112.
34. Kurihara Y, Hatori M, Ando Y, Ito D, Toyoshima T, Tanaka M, et al. Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via downregulation of matrix metalloproteinase-2 production and activation. Clin Exp Metastasis. 2009;26(5):425-32.
35. Pyo H, Choy H, Amorino GP, Kim JS, Cao Q, Hercules SK, et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res. 2001;7:2998-3005.
36. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage nonsmall- cell lung cancer. J Clin Oncol. 2003;21:2645-2650.
37. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX et al. Targeting cyclooxygenase 2 and HER- 2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology. 2001;120:1713-1719.
38. Kao J, Sikora AT, Fu S. Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma. Curr Cancer Drug Targets. 2009;9(8):931-7.
39. Segawa E, Sakurai K, Kishimoto H, Takaoka K, Noguchi K, Hashitani S, et al. Expression of cyclooxygenase-2 and DNA topoisomerase II alpha in precancerous and cancerous lesions of the oral mucosa. Oral Oncol. 2008;44(7):664-71.
40. Soland TM, Husvik C, Koppang HS, Boysen M, Sandvik L, Clausen OP, et al. A study of phosphorylated ERK1/2 and COX-2 in early stage (T1-T2) oral squamous cell carcinomas. J Oral Pathol Med. 2008;37(9):535-42.
41. Nystrom ML, McCulloch D, Weinreb PH et al. Cyclooxygenase- 2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion. Cancer Res. 2006; 66(22):10833-42.
42. Sakurai K, Urade M, Noguchi K et al. Prognostic significance of cyclooxygenase-2 and DNA topoisomerase IIalpha expression in oral carcinoma. Head Neck. 2007;29(11): 1002-9.
43. Sawhney M, Rohatgi N, Kaur J et al. Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco. Int J Cancer. 2007;120(12):2545-56.
44. Minter HA, Eveson JW, Huntley S, Elder DJ and Hague A. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res. 2003;9(5):1885-97.
45. Saba NF, Choi M, Muller S et al. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila Pa). 2009; 2(9):823-9.
46. Pandey M, Prakash O, Santhi WS, Soumithran CS and Pillai RM. Overexpression of COX-2 gene in oral cancer is independent of stage of disease and degree of differentiation. Int J Oral Maxillofac Surg. 2008;37:379-383.